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Purpose or Objective 
To evaluate the results of sentinel lymph node biopsy 
(SLNB) in patients diagnosed with a cT1-T2 oral squamous 
cell carcinoma and clinically negative (cN0) neck in the 
Netherlands. An update of this ongoing study will be 
presented. 
Material and Methods 
Retrospective analysis of 328 previously untreated 
patients, who underwent SLNB between 2007 and 2016. 
The SLNB procedure consisted of preoperative 
lymphoscintigraphy, intraoperative detection using 
gamma probe guidance and postoperative 
histopathological examination including step-serial 
sectioning and additional keratin immunohistochemical 
staining. A positive SLNB was followed by a neck 
dissection, while patients with a negative SLNB underwent 
regular follow-up with ultrasound guided fine-needle 
aspiration cytology on indication. 
Results 
The SLN identification rate was 98% (322/328). At least 
one histopathologically positive SLN was found in 77 of 322 
patients (24%). In 15 patients (19%) SLNs contained only 
isolated tumor cells as largest tumor deposit, in 28 
patients (36%) micrometastases and in 34 patients (44%) 
macrometastases. Median follow-up was 26 months (range 
1-104). During follow-up 18 patients developed isolated 
regional recurrence after a negative SLNB. Therefore, 
sensitivity of SLNB was 81% and the negative predictive 
value was 93%. The SLNB sensitivity of patients with a floor 
of mouth tumor was lower compared with tumors on other 
locations (67% vs. 84%, P=0.11), although the negative 
predictive value was comparable (92% vs. 93%). SLN-
negative patients showed a longer overall survival (78% vs. 
73%, P=<0.001) and disease specific survival (99% vs. 85%, 
P=<0.001) compared to SLN-positive patients. Isolated 
regional disease-free survival did not differ significantly 
(90% vs 87%, P=0.13). 
Conclusion 
SLNB is a safe and reliable diagnostic staging technique for 
detection of occult lymph node metastasis in patients with 
early stage (cT1-T2N0) oral cavity cancer, but needs 
improvement in patients with floor of mouth tumors. 
 
OC-021 Transoral Laser Microsurgery for T1a glottic 
cancer - DAHANCA 27 
N. Lyhne1, K. Hald2, T. Kjærgaard3, C. Godballe4, J. 
Tvedskov5, B. Ulhøj6, J. Overgaard7 
1Aarhus University Hospital, Department of Experimental 
Clinical Oncology and Department of Head and Neck 
Surgery, Aarhus C, Denmark; 2Aalborg University 
Hospital, Head and Neck Surgery, aalborg, 
Denmark; 3Aarhus University Hospital, Head and Neck 
Surgery, Aarhus C, Denmark; 4Odense University Hospital, 
Head and Neck Surgery, Odense, 
Denmark; 5Rigshospitalet, Head and Neck Surgery, 
København, Denmark; 6Aarhus University Hospital, 
Pathology, Aarhus C, Denmark; 7Aarhus University 
Hospital, Experimental Clinical Oncology, Aarhus C, 
Denmark  
 
Purpose or Objective 
The aim of this study was to evaluate whether treatment 
with transoral laser microsurgery (TLM) is non-inferior 
compared to accelerated radiotherapy (RT) in the 
treatment of T1aN0M0 glottic squamous cell carcinoma 
(SCC). 
The DAHANCA (Danish Head and Neck Cancer) database 
prospectively register all Danish patients diagnosed with a 
head and neck cancer. Hence, all patients diagnosed with 
a T1aN0M0 glottic SCC are registered, allowing for the 
analyses of potential selection biases into the DAHANCA 
27 study cohorts. 
Material and Methods 
Since 2003 the Danish national standard treatment for 
T1aN0M0 glottic SCC has been accelerated RT (66Gy, 33 
fractions,6 fractions/week). In 2012 cordectomy type I-III 
using TLM was introduced as an experimental treatment. 
The DAHANCA 27 trial is a comparative non-inferiority 
phase II study comparing two timely separated national 
patient cohorts. Patients treated with TLM from 
September 2012 to April 2016 were included in the TLM 
cohort, and patients treated with accelerated RT from 
January 2003 to august 2012 were included in the RT 
cohort. All patients are followed for five years or until 
death. The study will evaluate whether disease control 
after treatment with TLM is non-inferior compared to RT. 
Laryngectomy rate, survival and voice quality will also be 
analysed. 
Results 
A total of 94 patients were included in the TLM cohort and 
550 patients in the RT cohort. With an observation time of 
36 month, the proportion of local recurrence was 5.3% (5 
patients /94) in the TLM cohort and 4.4% (24 patients/ 
550) in the RT cohort. The proportion of successful salvage 
was 80% (4 patients /5) in the TLM cohort and 71% (17 
patients /24) in the RT cohort. The patient in the TLM 
cohort with non-cured recurrence initially rejected 
salvage treatment and was month later evaluated 
incurable. 
Conclusion 
Data show non-inferiority in disease control after TLM 
compared to RT. This study contributes to the 
international evidence regarding best practice in the 
treatment of T1aN0M0 glottic cancer due to the large 
national cohorts. The study outcome will determine 
whether TLM is implemented as a standard treatment for 
T1aN0M0 glottic cancer in Denmark. 
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Purpose or Objective 
Patients with oral squamous cell carcinomas (OSCC) suffer 
a high risk for local recurrences (10-30%) and have an 
annual risk of 3-4% for developing second primary 
tumours. In OSCC neck levels at risk for metastasis may be 
changed due to disruption of lymphatic channels by 
